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To assess the impact of concomitant inhibition of sodium-glucose cotransporter (SGLT) 2 and dipeptidyl
peptidase IV (DPP4) for the treatment of type 2 diabetesmellitus (T2DM), the effect of combined treatment
with canagliﬂozin, a novel SGLT2 inhibitor, and teneligliptin, a DPP4 inhibitor, on glucose intolerance was
investigated in Zucker diabetic fatty (ZDF) rats. Canagliﬂozin potently inhibited human and rat SGLT2 and
moderately inhibited human and rat SGLT1 activities but did not affect DPP4 activity. In contrast, ten-
eligliptin inhibited human and rat DPP4 activities but not SGLT activities. A single oral treatment of can-
agliﬂozin and teneligliptin suppressed plasma glucose elevation in an oral glucose tolerance test in 13
week-old ZDF rats. This combination of agents elevated plasma active GLP-1 levels in a synergistic
manner, probably mediated by intestinal SGLT1 inhibition, and further improved glucose intolerance. In
the combination-treated animals, there was no pharmacokinetic interaction of the drugs and no further
inhibition of plasma DPP4 activity compared with that in the teneligliptin-treated animals. These results
suggest that the inhibition of SGLT2 and DPP4 improves glucose intolerance and that combined treatment
with canagliﬂozin and teneligliptin is a novel therapeutic option for glycemic control in T2DM.
© 2015 Mitsubishi Tanabe Pharma Corporation. Production and hosting by Elsevier B.V. on behalf of
Japanese Pharmacological Society. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder
characterized by hyperglycemia resulting from decreased insulin
secretion and increased insulin resistance. Although a number of
oral antihyperglycemic agents are available and glucose-lowering
therapy is effective to prevent and manage diabetes and its com-
plications (1), it is still difﬁcult to maintain good glycemic control
with monotherapy over a long-term period because of their limited
efﬁcacy (2). Patients with inadequate glycemic control often require
additional combination therapy with other oral agents or insulin to
achieve the desired glycemic target levels (3).
Glucagon-like peptide-1 (GLP-1), an incretin hormone released
from L cells, exerts multiple antidiabetic effects such as stimulating
insulin secretion, inhibiting gastric emptying and glucagon secre-
tion, and suppressing appetite (4). Dipeptidyl peptidase IV (DPP4)o.jp (T. Oguma).
rmacological Society.
ation. Production and hosting by E
ecommons.org/licenses/by-nc-nd/4inhibitors prevent inactivation of incretins including GLP-1, facili-
tate incretin-induced insulin secretion, and control postprandial
blood glucose levels. Sodium glucose co-transporter (SGLT) 2 plays
a critical role in renal glucose reabsorption (5,6). SGLT2 inhibitors,
which enhance renal glucose excretion and reduce blood glucose
levels independent of insulin action, have been identiﬁed as a new
class of antihyperglycemic agents (7e10). Their use is associated
with a slight increase in the incidence of adverse events such as
urogenital infection and osmotic diuresis, which are considered to
be drug class effects (6). However, preclinical and clinical studies of
SGLT2 inhibitors have demonstrated the additional beneﬁcial ef-
fects of reducing body weight and blood pressure with low risk of
hypoglycemia (11e15).
A recent study has shown that canagliﬂozin, an SGLT2 inhibitor,
increases plasma GLP-1 concentrations in a mixed-meal tolerance
test in healthy subjects (16). Plasma concentrations of active and
total GLP-1 were further augmented in the combination treatment
with canagliﬂozin and a long-acting DPP4 inhibitor, teneligliptin, in
normoglycemic subjects (17). However, it is not knownwhether the
combination treatment controls hyperglycemia better than each
individual drug treatment in type 2 diabetes.lsevier B.V. on behalf of Japanese Pharmacological Society. This is an open access
.0/).
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concomitant inhibition of SGLT2 and DPP4, the combined effect of
teneligliptin and canagliﬂozin on glucose intolerance in an oral
glucose tolerance test (OGTT) was investigated in 13-week-old
Zucker diabetic fatty (ZDF) rats.
2. Materials and methods
2.1. Reagents and chemicals
Teneligliptin (98.8% purity) and canagliﬂozin (>99.95% purity)
were synthesized at Mitsubishi Tanabe Pharma Corporation (Toda-
shi, Saitama, Japan).
2.2. Cell-based assays
2.2.1. SGLTs inhibition assay
Expression plasmids containing human SGLT1 (hSGLT1), human
SGLT2 (hSGLT2), rat SGLT1 (rSGLT1), and rat SGLT2 (rSGLT2) were
stably transfected into Chinese hamster ovary (CHO)eK1 cells. Cells
were seeded into 24-well plates at a density of 4  105 cells/well in
Ham's F-12 medium containing 10% fetal bovine serum and were
incubated at 37 C in an assay buffer containing 50 mM HEPES,
20 mM Tris Base, 5 mM KCl, 1 mMMgCl2, 1 mM CaCl2, and 137 mM
NaCl at pH 7.4. SGLT1 and SGLT2 transporter activities were assayed
after 2 h of reaction time with 0.3 or 0.5 mM a-methyl-D-gluco-
pyranoside (AMG; SigmaeAldrich, St. Louis, MO) in the presence of
[14C]AMG (PerkinElmer, Waltham, MA). Radioactive counts in the
cells were determined using a liquid scintillation counter (Perki-
nElmer). Protein concentration was measured using the Coo-
massiePlus Protein Assay Kit (Pierce, Rockford, IL).
2.2.2. DPP4 inhibition assay
Inhibitory activities against human DPP4weremeasured using a
ﬂuorogenic DPP4 Assay Kit (BPS Bioscience, San Diego, CA). Test
compound solution, DPP substrate, and human recombinant DPP4
were mixed to initiate the enzyme reaction. After a 10 min reaction
at room temperature, the ﬂuorescence intensity was measured
using a microplate reader (Molecular Devices, Sunnyvale, CA).
Inhibitory activities against rat DPP4 were measured using
serum collected from 7-week-old male SpragueeDawley (SD) rats
(Charles River Japan, Yokohama, Japan). Rat serum and Glycyl-L-
proline 4-methylcoumaryl-7-amide (MCA) were mixed with PBS
containing 0.003% Brij-35 to initiate the enzyme reaction, as pre-
viously described (18). The ﬂuorescence intensity of MCA was
measured using a microplate reader after a 1-h incubation at 37 C.
2.3. In vivo studies
2.3.1. Animals and test compound administration
All animal experimental procedures were approved by the
Institutional Animal Care and Use Committee of Mitsubishi Tanabe
Pharma Corporation or LSI Medience Corporation (Tokyo, Japan)
and met the Japanese Experimental Animal Research Association
standards, as deﬁned in the Guidelines for Animal Experiments
(1987). Male ZDF-Leprfa/CrlCrlj rats were purchased from Charles
River Japan. During an acclimatization period of 6 weeks, the ani-
mals were housed with a 12-h light/dark cycle and controlled
temperature and humidity. Rats were provided water ad libitum
and a standard commercial diet. Test compounds for oral gavage
were prepared in 0.5% hydroxypropyl methylcellulose.
2.3.2. OGTT in ZDF rats
Because female ZDF rats rarely exhibit hyperglycemia, despite
obesity and insulin resistance comparable to males (20,23), weperformed the experiments only inmale rats.We used 13-week-old
animals because previous studies have demonstrated normal
creatinine clearance in the age range of 16e20 weeks in ZDF rats
(20e24). After overnight fasting, test drugs were orally adminis-
tered to 13-week-old ZDF rats in a volume of 5 mL/kg. The
administered doses were 0.3 mg/kg for teneligliptin, 3 and 10 mg/
kg for canagliﬂozin, and a combination of 0.3 mg of teneligliptin
and 3 or 10 mg/kg of canagliﬂozin. Teneligliptin at 0.1 mg/kg and
1 mg/kg inhibits >50% of plasma DPP4 activity for 30 min and
signiﬁcantly reduces postprandial hyperglycemia in Zucker fatty
rats (18), and canagliﬂozin at 3 mg/kg and 30 mg/kg inhibits >70%
of renal glucose reabsorption in ZDF rats (19). Glucose solution was
orally administered at 2 g/kg body weight 15 min after the
administration of the test compounds, and blood was collected
from the tail vein into chilled tubes containing EDTA and a DPP4
inhibitor 15 min before (15) and 0, 10, 30, 60, and 120 min after
the oral glucose administration. Plasma was separated by centri-
fugation and stored at 80 C until the measurement of plasma
glucose, insulin, and aGLP-1 concentrations.
2.3.3. Determination of metabolic parameters
Plasma glucose concentrations were determined using a
Glucose CII-Test WAKO Kit (Wako Pure Chemical Industries, Osaka,
Japan). Plasma active GLP-1 (aGLP-1) concentrations were
measured using an ELISA kit (Epitope Diagnostics, Inc., San Diego,
CA) after solid phase extraction. Plasma insulin concentrations
were measured with an enzyme-linked immunosorbent assay kit
(Morinaga Institute of Biologic Science, Yokohama, Japan). Plasma
DPP4 activities were measured as described above.
2.3.4. Pharmacokinetic study
Plasma concentrations of canagliﬂozin and teneligliptin were
determined in satellite groups of 13 week-old ZDF rats by liquid
chromatography-tandem mass spectrometry (LC-MS/MS) after
solid-phase extraction from plasma. In brief, test compounds and
glucose were orally administered to ZDF rats as mentioned above.
The same volume of drug or vehicle was administered in both
single and combination treatment groups. Plasma samples were
collected at 0.25, 0.42, 0.75,1.25, 2.25, 4, 8,10, 24, and 32 h after test
compound administration. Each sample was loaded onto an OASIS
HLB mElution 96-well plate (30 mm, Waters Corporation, Milford,
MA) and eluted with acetonitrile. The eluates were injected into an
API4000 mass spectrometer (AB SCIEX, Framingham, USA) equip-
ped with an Atlantis C18 column (5 mm, 2.1 mm I.D.  50 mm;
Waters Corporation) for teneligliptin or a Cadenza CD C-18 column
(2.0 mm I.D.  50 mm, 3 mm, Imtakt Corporation, Kyoto, Japan) for
canagliﬂozin. The pharmacokinetic parameters were determined
using the pharmacokinetic analysis software Phoenix WinNonlin
6.3 (Pharsight Corporation, RealMountain View, USA).
2.4. Statistical analysis
Data were presented as the mean ± S.E.M. for each group. Sta-
tistical analyses were performed using an SAS-based system (SAS
Institute, Cary, NC, USA) or Prism software (GraphPad, San Diego,
CA, USA), and signiﬁcant differences were identiﬁed using a para-
metric Dunnett's multiple comparison test, t-test, or two way
analysis of variance, as appropriate. Probabilities less than 5%
(P < 0.05) were considered to be statistically signiﬁcant. Integrated
plasma glucose, aGLP-1, and insulin levels during OGTT were
expressed as the incremental area under the curve (DAUC0e2h),
calculated by the trapezoidal rule. The peak value of plasma
glucose, aGLP-1, and insulin above baseline levels measured at
0 min was calculated up to 120 min after glucose loading.
Table 1
IC50 values for SGLT1, SGLT2, and DPP4 activities of canagliﬂozin and teneligliptin.
IC50 (nmol/L) Human Rat
SGLT1 SGLT2 DPP4 SGLT1 SGLT2 DPP4
Canagliﬂozin 663 ± 180a 4.2 ± 1.5a >10,000 555 ± 31a 3.7 ± 0.2a >10,000
Teneligliptin >10,000 >10,000 3.66
(1.29e10.45)
>10,000 >10,000 0.76
(0.33e1.77)
Values were expressed as the geometric mean of three sets of experiments with 95% conﬁdence intervals.
a Values were expressed as mean ± SEM of 3e4 experiments. Data from Kuriyama et al. (12).
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3.1. SGLT and DPP4 inhibition
Table 1 shows the IC50 values of canagliﬂozin and teneligliptin
against human and rat SGLT1, SGLT2, and DPP4 activities. As pre-
viously reported, canagliﬂozin inhibited SGLT2 potently and
moderately inhibited both human and rat SGLT1 activities (19). The
IC50 ratio for SGLT1 to SGLT2 was approximately 150e160. Ten-
eligliptin did not inhibit SGLT1 and SGLT2 activities (IC50 > 10 mmol/
L). Human and rat DPP4 activities were inhibited by teneligliptin
but not by canagliﬂozin.Fig. 1. Effects of treatment with a combination of canagliﬂozin and teneligliptin during OGT
or both canagliﬂozin and teneligliptin by oral gavage. After 15 min, glucose solutions at 2 g/k
points of 15, 0, 10, 30, 60, and 120 min after oral glucose administration. (A) Time course o
Time course of plasma insulin levels (ng/mL). Data are presented as the mean ± S.E.M. (N3.2. Effect of the combination of canagliﬂozin and teneligliptin on
plasma levels of glucose, insulin, and aGLP-1 during OGTT in ZDF rats
The fasting plasma glucose level was 423.2 mg/dL, and the
plasma glucose level was elevated to 692.0 mg/dL in the vehicle-
treated ZDF rats, which showed development of marked fasting
hyperglycemia and glucose intolerance. Both teneligliptin (0.3 mg/
kg) and canagliﬂozin (3 and 10 mg/kg) signiﬁcantly suppressed the
elevation of plasma glucose levels after glucose loading (Fig. 1A and
Table 2). Treatment with a combination of teneligliptin and cana-
gliﬂozin further inhibited the excursion of plasma glucose levels
compared to each of the single treatments.T in ZDF rats. Thirteen-week-old ZDF rats were administered canagliﬂozin, teneligliptin,
g were orally administered to the rats, and blood was collected from the tail vein at time
f plasma glucose levels (mg/dL). (B) Time course of plasma aGLP-1 levels (pmol/L). (C)
¼ 8).
Fig. 2. The effect of combined treatment with canagliﬂozin and teneligliptin on plasma
DPP4 activity in ZDF rats. Canagliﬂozin, teneligliptin, or both canagliﬂozin and ten-
eligliptin were administered to 13-week-old ZDF rats by oral gavage, and blood was
collected from the tail vein 15 min after the treatment. Inhibition rate was expressed as
[1 e DPP4 activity after drug/DPP4 activity after vehicle]  100 (%). Data are presented
as the mean ± S.E.M. (N ¼ 8).
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treated ZDF rats and increased to 0.90 pmol/L 15 min after ten-
eligliptin treatment, conﬁrming systemic DPP4 inhibition following
teneligliptin treatment. Glucose administration transiently
increased the plasma aGLP-1 level. The peak level of plasma aGLP-1
was elevated by teneligliptin alone; however, the DAUC0e2h of
aGLP-1 levels was not signiﬁcantly different (Fig. 1B and Table 2).
Canagliﬂozin did not affect the DAUC0e2h and peak plasma aGLP-1
levels in the OGTT at either doses studied. The difference in the
DAUC0e2h and peak plasma aGLP-1 levels from basal levels was
enhanced in the combined treatment group compared with in the
teneligliptin treatment group (Fig. 1B and Table 2).
ZDF rats exhibited fasting hyperinsulinemia and markedly
diminished glucose-induced insulin secretion compared with lean
rats (20,21). The plasma insulin levels in the OGTT were increased
with teneligliptin treatment (Fig. 1C and Table 2) but were not
affected with canagliﬂozin treatment. Combined drug treatment
signiﬁcantly increased glucose-induced insulin secretion compared
with that in canagliﬂozin treatment group. The peak of insulin level
during the OGTT in the combination treatment group was lower
than that in the teneligliptin treatment group, although the
DAUC0e2h did not differ between the two treatment groups.
Plasma DPP4 activity was inhibited by approximately 75% with
teneligliptin treatment and combined canagliﬂozin and ten-
eligliptin treatment in ZDF rats (Fig. 2).3.3. Pharmacokinetic study in ZDF rats
The plasma concentrations of unchanged canagliﬂozin (3 and
10 mg/kg) increased and reached the peak levels within 4 h after
administration, and then gradually decreased with t1/2 values of
approximately 6 h (Fig. 3A). The time course of plasma concen-
tration and t1/2 was almost the same with the concomitant treat-
ment of teneligliptin (0.3 mg/kg). The peak plasma teneligliptin
level was approximately 30 min after treatment and the plasma
teneligliptin level gradually decreased with t1/2 values of approxi-
mately 10 h (Fig. 3B). Time course changes and t1/2 in plasma levels
of teneligliptin were not affected by the concomitant administra-
tion of canagliﬂozin at 3 and 10 mg/kg.4. Discussion
In the present study, combined treatment with canagliﬂozin and
teneligliptin improved glucose intolerance and synergistically
increased plasma aGLP-1 levels in ZDF rats, a widely used geneticTable 2
Descriptive statistics of the peak levels and DAUC0e2h of plasma glucose, aGLP-1, and ins
Glucose
Peak (mg/dL) DAUC0e2h
(h$mg/dL)
Vehicle 302.11 ± 13.11 24846.0 ± 11
Teneligliptin (0.3 mg/kg) 199.86 ± 7.03## 18207.4 ± 55
Canagliﬂozin (3 mg/kg) 146.20 ± 15.51** 6935.3 ± 11
Canagliﬂozin (10 mg/kg) 53.00 ± 10.35** 1622.4 ± 84
Teneligliptin (0.3 mg/kg) þ Canagliﬂozin (3 mg/kg) 45.81 ± 9.48$$,yy 21.3 ± 96
Teneligliptin (0.3 mg/kg) þ Canagliﬂozin (10 mg/kg) 0.91 ± 0.91$$,zz 6215.8 ± 11
All values are presented as mean ± SEM (N ¼ 8).
#P < 0.05.
##P < 0.01 vs. vehicle-treated group (t-test).
**P < 0.01 vs. vehicle-treated group (Dunnett's test).
$P < 0.05.
$$P < 0.01 vs. teneligliptin-treated group (Dunnett's test).
yyP < 0.01 vs. canagliﬂozin (3 mg/kg)-treated group (t-test).
zzP < 0.01 vs. canagliﬂozin (10 mg/kg)-treated group (t-test).model of obese T2DM (20e24). Canagliﬂozin did not affect DPP4
activity, and teneligliptin did not inhibit SGLTs activity in vitro. In
addition, pharmacokinetic analysis revealed that there was no
drugedrug interaction between canagliﬂozin and teneligliptin.
Plasma DPP4 activity in ZDF rats was similarly inhibited by the
treatment with teneligliptin alone and with the combination of
these two drugs. Thus, the increase of glucose-induced plasma
aGLP-1 levels is likely to be due to enhanced secretion of GLP-1 by
canagliﬂozin and not potentiation of each mechanism.
SGLT1 plays a critical role in dietary glucose absorption in the
gastrointestinal tract, and acts as a glucose sensor for GLP-1
secretion from L cells (25,26). In contrast, SGLT1 inhibitors in-
crease plasma GLP-1 levels in diabetic rodents (27,28). Thus, the
role of SGLT1 in secreting GLP-1 is still controversial. We have
previously demonstrated the elevation of plasma aGLP-1 levels by
SGLT1 inhibition during OGTT in normal rodents (29). Clinical
studies in healthy subjects have also revealed delayed glucose
absorption and elevated plasma GLP-1 levels in a mixed-meal test
with canagliﬂozin, which inhibits SGLT1 activity at a concentra-
tion approximately 150e160 times higher than that for SGLT2
(16). The intraluminal concentration of canagliﬂozin is likely to be
high enough to inhibit SGLT1 in the small intestines after oral
administration, whereas the plasma concentration ofulin during OGTT in ZDF rats.
aGLP-1 Insulin
Peak (pmol/L) DAUC0e2h
(h$pmol/L)
Peak (ng/L) DAUC0e2h
(h$ng/L)
00.7 0.258 ± 0.136 3.1 ± 3.1 1.383 ± 0.293 20.4 ± 8.8
4.4## 0.820 ± 0.179# 24.1 ± 18.4 4.375 ± 0.775## 120.1 ± 27.2##
78.7** 0.460 ± 0.096 10.5 ± 2.7 0.438 ± 0.087** 11.3 ± 6.2
7.8** 0.506 ± 0.124 12.5 ± 4.6 0.401 ± 0.080** 20.4 ± 8.1
3.2$$,yy 4.324 ± 0.974$$,yy 64.4 ± 34.9$ 2.405 ± 0.324$,yy 102.3 ± 21.6yy
29.4$$,zz 4.265 ± 0.735$$,zz 141.1 ± 21.1$$,zz 1.636 ± 0.136$$,zz 84.5 ± 8.6zz
Fig. 3. Time course of plasma levels of unchanged canagliﬂozin and teneligliptin after single or concomitant administration in ZDF rats. Thirteen-week-old ZDF rats were
administered canagliﬂozin, teneligliptin, or both canagliﬂozin and teneligliptin by oral gavage. After 15 min, glucose solution at 2 g/kg was orally administered to the rats, and blood
was collected from the subclavian vein at time points of 0.25, 0.42, 0.75, 1.25, 2.25, 4, 8, 10, 24, and 32 h after test compound administration. Plasma concentrations of canagliﬂozin
(A) and teneligliptin (B) were determined using LC-MS/MS as described in the methods. Data are presented as the mean þ S.D. (N ¼ 4).
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temically (19). A previous study has shown that suppressed
glucose excursion is at least partly mediated by enhanced GLP-1
secretion during OGTT in SGLT1/ mice (30). Similar to this
SGLT1 knockout model, the combination treatment, compared
with the teneligliptin alone treatment, markedly augmented
plasma aGLP-1 concentrations along with a much improved
glucose tolerance in ZDF rats in the present study. Thus, it is likely
that intestinal SGLT1 inhibition contributes to improve glucose
tolerance by canagliﬂozin when combined with teneligliptin.
Systemic SGLT2 inhibition does not affect GLP-1 secretion
because there are no changes in plasma GLP-1 levels in SGLT2-
deﬁcient mice after glucose-loading (28). Thus, although cana-
gliﬂozin is an SGLT2 inhibitor, SGLT2 inhibition would not
contribute to the elevation in plasma aGLP-1 levels in ZDF rats. It
is likely that orally administered canagliﬂozin delays the ab-
sorption of glucose through inhibition of SGLT1 in the upper part
of the small intestine and that GLP-1 is secreted because of
increased glucose levels in the distal part of the small intestine.
While the glucose excursion in the combination group was
greatly suppressed compared with that in the teneligliptin group in
the OGTT, the increase of insulin levels was similar between these
groups. Canagliﬂozin decreases blood glucose levels by enhancing
excretion of glucose from the kidney independent of insulin action
in hyperglycemic conditions. The similar insulin release with a
small increment of glucose level shows that the glucose-induced
insulin release mechanism was greatly enhanced with the addi-
tion of canagliﬂozin in the teneligliptin-treated hyperglycemic rats.
In contrast to the insulin level, the plasma aGLP-1 level was greatly
elevated in the rats with combination treatment group compared
with those in the teneligliptin treatment group. Because aGLP-1
enhances glucose-induced insulin release, it is suggested that the
plasma aGLP-1 elevation by combined treatment facilitated
glucose-induced insulin release in the OGTT.
Glucose excursion in the OGTT was greatly reduced with com-
bination treatment compared with the canagliﬂozin treatment
alone. GLP-1 is an incretin hormone that enhances postprandial
insulin secretion. Both aGLP-1 and insulin concentrations were
greatly enhanced by the combination treatment compared with the
canagliﬂozin treatment. It is reasonable to assume that increased
plasma insulin levels further reduces glucose excursion during
OGTT with combined treatment. Therefore, elevation of aGLP-1levels in combination with teneligliptin may add therapeutic
value in the control of glucose intolerance.
A number of SGLT2 inhibitors have been reported in non-clinical
and clinical studies. Among them, canagliﬂozin is an SGLT2 inhib-
itor with moderate inhibitory activity for hSGLT1, which is unlike
other highly selective SGLT2 inhibitors (31). Thus, it is not certain
whether the synergistic effect on GLP-1 secretion with combined
treatment of a DPP4 inhibitor is shared with other highly selective
SGLT2 inhibitors. In addition to established treatments with SGLT2
inhibition and DPP4 inhibition in T2DM patients, treatment with a
combination of canagliﬂozin and a DPP4 inhibitor would be asso-
ciated with multiple antidiabetic effects of GLP-1 in the treatment
of T2DM.
Taken together, the combined treatment of canagliﬂozin and
teneligliptin improved glucose intolerance with similar insulin
release when compared to teneligliptin treatment alone. Combined
treatment also stimulated insulin release when compared to the
canagliﬂozin treatment alone. Although canagliﬂozin is an SGLT2
inhibitor, the combination effect is likely to be partly mediated by
its inhibitory action on intestinal SGLT1. Given the low incidence of
side effects of hypoglycemia, weight gain, and abdominal symp-
toms with SGLT2 and DPP4 inhibitors (32,33), combined treatment
with canagliﬂozin and teneligliptin would be a good option for
treatment of T2DM.
Conﬂicts of interest
All the authors are employees of Mitsubishi Tanabe Pharma
Corporation.
References
(1) UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose con-
trol with sulphonylureas or insulin compared with conventional treatment
and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet.
1998;352:837e853.
(2) Lebovitz HE. Oral antidiabetic agents. In: Kahn CR, Weir GC, editors. Joslin's
diabetes mellitus. 13th ed. Philadelphia: Lea & Febiger; 1994. p. 508e529.
(3) DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern
Med. 1999;131:281e303.
(4) Meier JJ, Nauck MA. Glucagon-like peptide 1(GLP-1) in biology and pathology.
Diabetes Metab Res Rev. 2005;21:91e117.
(5) Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low afﬁnity
Naþ/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive
mechanism for D-glucose. J Clin Invest. 1994;93:397e404.
T. Oguma et al. / Journal of Pharmacological Sciences 127 (2015) 456e461 461(6) Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotrans-
porter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev.
2011;32:515e531.
(7) Oku A, Ueta K, Arakawa K, Ishihara T, Nawano M, Kuronuma Y, et al. T-1095,
an inhibitor of renal Naþ-glucose cotransporters, may provide a novel
approach to treating diabetes. Diabetes. 1999;48:1794e1800.
(8) Oku A, Ueta K, Nawano M, Arakawa K, Kano-Ishihara T, Matsumoto M, et al.
Antidiabetic effect of T-1095, an inhibitor of Na(þ)-glucose cotransporter, in
neonatally streptozotocin-treated rats. Eur J Pharmacol. 2000;391:183e192.
(9) Arakawa K, Ishihara T, Oku A, Nawano M, Ueta K, Kitamura K, et al. Improved
diabetic syndrome in C57BL/KsJ-db/dbmice by oral administration of the Na(þ)-
glucose cotransporter inhibitor T-1095. Br J Pharmacol. 2001;132:578e586.
(10) Ueta K, Ishihara T, Matsumoto Y, Oku A, Nawano M, Fujita T, et al. Long-term
treatment with the Naþ-glucose cotransporter inhibitor T-1095 causes sus-
tained improvement in hyperglycemia and prevents diabetic neuropathy in
Goto-Kakizaki Rats. Life Sci. 2005;76:2655e2668.
(11) Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Efﬁcacy and
safety of canagliﬂozin versus glimepiride in patients with type 2 diabetes
inadequately controlled with metformin (CANTATA-SU): 52 week results
from a randomised, double-blind, phase 3 non-inferiority trial. Lancet.
2013;382:941e950.
(12) Liang Y, Arakawa K, Ueta K, Matsushita Y, Kuriyama C, Martin T, et al. Effect of
canagliﬂozin on renal threshold for glucose, glycemia, and body weight in
normal and diabetic animal models. PLoS One. 2012;7:e30555.
(13) Weir MR, Januszewicz A, Gilbert RE, Vijapurkar U, Kline I, Fung A, et al. Effect
of canagliﬂozin on blood pressure and adverse events related to osmotic
diuresis and reduced intravascular volume in patients with type 2 diabetes
mellitus. J Clin Hypertens. 2014;16:875e882.
(14) Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, et al. Ef-
ﬁcacy and safety of canagliﬂozin over 52 weeks in patients with type 2 dia-
betes on background metformin and pioglitazone. Diabetes Obes Metab.
2014;16:467e477.
(15) Watanabe Y, Nakayama K, Taniuchi N, Horai Y, Kuriyama C, Ueta K, et al.
Beneﬁcial effects of canagliﬂozin in combination with pioglitazone on insulin
sensitivity in rodent models of obese type 2 diabetes. PLoS One. 2015;10:
e0116851.
(16) Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, et al. Canagli-
ﬂozin lowers postprandial glucose and insulin by delaying intestinal glucose
absorption in addition to increasing urinary glucose excretion: results of a
randomized, placebo-controlled study. Diabetes Care. 2013;36:2154e2161.
(17) Kinoshita S, Kondo K. Evaluation of pharmacokinetic and pharmacodynamic
interactions of canagliﬂozin and teneligliptin in Japanese healthy male vol-
unteers. Expert Opin Drug Metab Toxicol. 2015;11:7e14.
(18) Fukuda-Tsuru S, Anabuki J, Abe Y, Yoshida K, Ishii S. A novel, potent, and long-
lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial
hyperglycemia and dyslipidemia after single and repeated administrations.
Eur J Pharmacol. 2012;696:194e202.
(19) Kuriyama C, Xu JZ, Lee SP, Qi J, Kimata H, Kakimoto T, et al. Analysis of the
effect of canagliﬂozin on renal glucose reabsorption and progression ofhyperglycemia in Zucker diabetic fatty rats. J Pharmacol Exp Ther. 2014;351:
423e431.
(20) Clark JB, Palmer CJ, Shaw WN. The diabetic Zucker fatty rat. Proc Soc Exp Biol
Med. 1983;173:68e75.
(21) Tokuyama Y, Sturis J, DePaoli AM, Takeda J, Stoffel M, Tang J, et al. Evolution of
beta-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes. 1995;44:
1447e1457.
(22) Peterson RG, ShawWN, Neel MA, Little LA, Eichberg J. Zucker diabetic fatty rat
as a model for non-insulin-dependent diabetes mellitus. ILAR J. 1990;32:
16e19.
(23) Sz€ocs Z, Brunmair B, Stadlbauer K, Nowotny P, Bauer L, Luger A, et al. Age-
dependent development of metabolic derangement and effects of interven-
tion with pioglitazone in Zucker diabetic fatty rats. J Pharmacol Exp Ther.
2008;326:323e329.
(24) Toblli JE, Ferrini MG, Cao G, Vernet D, Angerosa M, Gonzalez-Cadavid NF.
Antiﬁbrotic effects of pioglitazone on the kidney in a rat model of type 2
diabetes mellitus. Nephrol Dial Transpl. 2009;24:2384e2391.
(25) Moriya R, Shirakura T, Ito J, Mashiko S, Seo T. Activation of sodium-glucose
cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion
in mice. Am J Physiol Endocrinol Metab. 2009;297:E1358eE1365.
(26) Gorboulev V, Schürmann A, Vallon V, Kipp H, Jaschke A, Klessen D, et al.
Na(þ)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose ab-
sorption and glucose-dependent incretin secretion. Diabetes. 2012;61:
187e196.
(27) Shibazaki T, Tomae M, Ishikawa-Takemura Y, Fushimi N, Itoh F, Yamada M,
et al. KGA-2727, a novel selective inhibitor of a high-afﬁnity sodium glucose
cotransporter (SGLT1), exhibits antidiabetic efﬁcacy in rodent models.
J Pharmacol Exp Ther. 2012;342:288e296.
(28) Powell DR, Smith M, Greer J, Harris A, Zhao S, DaCosta C, et al. LX4211 in-
creases serum glucagon-like peptide 1 and peptide YY levels by reducing
sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal
glucose. J Pharmacol Exp Ther. 2013;345:250e259.
(29) Oguma T, Nakayama K, Watanabe Y, Kuriyama C, Kimata H, Yoshida K, et al.
Combination with SGLT inhibitor and DPP4 inhibitor increases plasma active
GLP-1 levels. In the 56th Annual Meeting of the Japan Diabetes Society,
Kumamoto, Japan. 2013. II-P-141.
(30) Powell DR, DaCosta CM, Gay J, Ding ZM, Smith M, Greer J, et al. Improved
glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol
Metab. 2013;304:E117eE130.
(31) Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, et al.
Empagliﬂozin, a novel selective sodium glucose cotransporter-2 (SGLT-2)
inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
Diabetes Obes Metab. 2012;14:83e90.
(32) Abdul-Ghani MA, Norton L, DeFronzo RA. Efﬁcacy and safety of SGLT2 in-
hibitors in the treatment of type 2 diabetes mellitus. Curr Diab Rep. 2012;12:
230e238.
(33) Stein SA, Lamos EM, Davis SN. A review of the efﬁcacy and safety of oral
antidiabetic drugs. Expert Opin Drug Saf. 2013;12:153e175.
